Chugai, a member of Roche group, is a Japanese company focused on creating innovative medicinal products which address unmet medical needs. Our innovative antibody technologies have led to multiple therapeutics helping patients around the world. We are the leaders in oncology therapeutics in Japan and have an overall top-level presence in the Japanese pharmaceutical industry. Our proprietary products, discovered and developed by Chugai, include the anti-IL-6 monoclonal antibody Actemra®/RoActemra®, ALK inhibitor Alecensa® and anti-FlXa/FX bispecific antibody Hemlibra®, all of which are approved worldwide and illustrate our robust drug R&D capabilities. Chugai is keen to collaborate with companies with innovative drug discovery technologies. As well, we seek clinical stage licensing opportunities in the oncology, ophthalmology, neuroscience, immunology and cardiovascular metabolism areas. Our territory is not only in Japan but also EU and potentially other rest of the world.